EventsThe 7th International Multidisciplinary Conference on Optofluidics 2017
Published
This submission belongs to the session 16. Lab on a chip of the event The 7th International Multidisciplinary Conference on Optofluidics 2017
Published date
21 Jul, 2017
Citation
Peng SHI, High-throughput Brain Activity Mapping as a Foundation for Systems Neuropharmacology, in Proceedings of The 7th International Multidisciplinary Conference on Optofluidics 2017, Singapore, 25 July–28 July 2017, MDPI: Basel, Switzerland, doi: 10.3390/optofluidics2017-04499
Share
Email
Facebook
Twitter
LinkedIn

High-throughput Brain Activity Mapping as a Foundation for Systems Neuropharmacology

image
1. City University of Hong Kong
Abstract

Technologies for mapping dynamic patterns of neural activity over time and space have advanced our understanding of brain function in both health and disease. An important application of these technologies is the discovery of next-generation neurotherapeutics for neurological and psychiatric disorders lacking effective treatments. Here, we describe an in vivo drug screening strategy that combines high-throughput brain activity mapping (BAM) technology with bioinformatic analysis. This platform enables evaluation of a compound’s therapeutic potential based on information rich BAMs derived from drug-treated zebrafish larvae. From a screen of clinically used drugs, we found intrinsically coherent drug clusters that are significantly associated with known therapeutic categories. Using the BAM-based clusters as a functional classifier, we successfully predicted anti-epileptic candidate drugs from non-clinical compounds and implicate epigenetic mechanisms for the development of novel anti-epileptic drugs. Collectively, these BAMs linked to specific compounds provide an experimental framework to advance the field of systems neuropharmacology.

Keywords
HIGH-RESOLUTION DEAN FLOW FRACTIONATION (HiDFF): A NOVEL DEAN MIGRATION PHENOMENON FOR SMALL MICROPARTICLE SEPARATION
In vitro micro-physiological models for predictive toxicology and disease modelling